Literature DB >> 16134309

Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma.

B Wang1, Z Q Gao, X Yan.   

Abstract

PURPOSE: To explore the correlation between contrast-enhancement patterns on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and angiogenesis by analyzing microvessel density (MVD), vascular endothelial growth factor (VEGF), and P53 protein expression in hepatocellular carcinoma (HCC).
MATERIAL AND METHODS: MRI was performed with a GE Signa 1.5T MR scanner using SE and FMPSPGR sequences in 30 patients (38 lesions) during the period October 1998 to March 2000. All had histopathologically proven HCC. MR images were reviewed/ analyzed retrospectively. The 30 patients were between 35 and 65 years of age (average age 58; 18 M and 12 F). SE T1WI, PDWI, and T2WI were acquired initially. The FMPSPGR sequence was acquired in the same position. The DCE-MRI was performed in the arterial, portal vein, and delay phase after a bolus injection of Gd-DTPA. The specimens were stained immunohistochemically for CD34, VEGF, and P53. MVD was highlighted by anti-CD34 antibody staining. The enhancement features of HCC lesions were studied correlatively with the tumor MVD, VEGF, and P53 expression at protein level.
RESULTS: In the arterial phase, the results showed that MVD of HCC in the high-enhancement group (229.76 +/- 80.96) was higher than that in the equal-enhancement (173.09 +/- 61.38) and low-enhancement groups (153.00 +/- 108.58) (P < 0.01, respectively). VEGF expression of HCC in the high-enhancement group (68.42%) was higher than that in the equal-enhancement (36.36%) and low-enhancement groups (38.89%) (P < 0.05, respectively). In the portal vein phase, MVD of HCC in the enhancement group (259.80 +/- 93.30) was higher than that in the non-enhancement group (178.64 +/- 92.65) (P < 0.05). No significant correlation was found between VEGF expression and the enhancement feature in the portal vein phase. In the delay phase, MVD of HCC in the ring-enhancement group (269.06 +/- 57.89) was significantly higher than that in the non-ring-enhancement group (144.10 +/- 88.90) (P < 0.01). There was a significant difference in VEGF expression between the ring-enhancement group (76.47%) and the non-ring-enhancement group (42.86%) (P < 0.05). No significant correlation was detected between P53 protein expression and the enhancement feature. Relative enhancement (RE) correlated with MVD, but not with VEGF and P53 protein expression.
CONCLUSION: The contrast-enhancement patterns on DCE-MRI are influenced by tumor angiogenesis, as reflected by elevated VEGF expression, and are therefore valuable indicators for accessing tumor angiogenic activity and tumor neovascularization in vivo in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134309     DOI: 10.1080/02841850510021247

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  17 in total

1.  Incorporating the effects of transcytolemmal water exchange in a reference region model for DCE-MRI analysis: theory, simulations, and experimental results.

Authors:  Thomas E Yankeelov; Jeffrey J Luci; Laura M DeBusk; P Charles Lin; John C Gore
Journal:  Magn Reson Med       Date:  2008-02       Impact factor: 4.668

2.  Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density.

Authors:  Naoko Mori; Hiroyuki Abe; Shunji Mugikura; Chiaki Takasawa; Satoko Sato; Minoru Miyashita; Yu Mori; Federico D Pineda; Gregory S Karczmar; Hajime Tamura; Shoki Takahashi; Kei Takase
Journal:  Acad Radiol       Date:  2018-09-28       Impact factor: 3.173

Review 3.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 4.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

5.  Temporal analysis of tumor heterogeneity and volume for cervical cancer treatment outcome prediction: preliminary evaluation.

Authors:  Jeffrey W Prescott; Dongqing Zhang; Jian Z Wang; Nina A Mayr; William T C Yuh; Joel Saltz; Metin Gurcan
Journal:  J Digit Imaging       Date:  2009-01-27       Impact factor: 4.056

Review 6.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics.

Authors:  Wenjiao Zeng; Annette S H Gouw; Marius C van den Heuvel; Grietje Molema; Sibrand Poppema; Eric J van der Jagt; Koert P de Jong
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344

9.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.

Authors:  Thomas E Yankeelov; John C Gore
Journal:  Curr Med Imaging Rev       Date:  2009-05-01

10.  Intravital assessment of angioarchitecture in rat hepatocellular nodules using in vivo fluorescent microscopy.

Authors:  Yi Liu; Tao Lu; Congcong Wang; Hui Li; Ke Xu; Peiling Li
Journal:  Quant Imaging Med Surg       Date:  2019-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.